An announcement from Silo Pharma ( (SILO) ) is now available.
Silo Pharma has released a presentation detailing its strategic initiatives and drug development pipeline, which will be available on its website from March 10, 2025. The company is advancing its lead asset, SPC-15, towards first-in-human clinical trials, pending FDA guidance, and has secured exclusive global licenses from Columbia University for two portfolio assets. Silo Pharma plans to utilize the FDA’s streamlined 505(b)(2) regulatory pathway for its priority drug candidates, SPC-15 and SP-26, to expedite drug approval. The company is well-positioned in the central nervous system therapeutics industry with a diversified pipeline, strong intellectual property portfolio, and sufficient capital resources to support upcoming catalysts.
More about Silo Pharma
Silo Pharma, Inc. is a developmental stage biopharmaceutical company focused on creating novel therapeutics for unmet medical needs, particularly in the areas of post-traumatic stress disorder (PTSD), stress-induced psychiatric disorders, fibromyalgia, chronic pain disorders, and central nervous system diseases. The company is developing both traditional therapies and psychedelic treatments with innovative formulations and drug delivery systems.
YTD Price Performance: 36.84%
Average Trading Volume: 3,246,686
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.83M
For a thorough assessment of SILO stock, go to TipRanks’ Stock Analysis page.